在组合治疗下,AIH-PBC变体综合征的诊断标准和长期结果
Anna E C Stoelinga1, Maaike Biewenga1, Joost P H Drenth2,3
1Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands.
JHEP reports : innovation in hepatology
|July 8, 2024
概括
自身免疫性肝炎 - 初级胆道胆炎 (AIH-PBC) 患者通常不符合巴黎标准,但对联合治疗反应良好. 患有PBC和炎症的患者比接受AIH-PBC治疗的患者表现更差,这表明治疗的益处更广泛.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 自免疫性肝脏疾病是什么?
- 临床诊断 临床诊断 临床诊断
背景情况:
- 自免疫性肝炎 (AIH) 和一次性胆道胆炎 (PBC) 可以同时存在,形成AIH-PBC综合征.
- 联合免疫抑制和ursodeoxycholic acid (UDCA) 是AIH-PBC的标准治疗方法.
- 当前的诊断标准,如巴黎标准,可能无法识别所有符合条件的患者.
研究的目的:
- 评估用于诊断AIH-PBC的巴黎和张标准的实用性和临床相关性.
- 根据诊断标准的遵守,比较AIH-PBC患者的结果.
- 评估PBC肝炎对长期生存的影响.
主要方法:
- 对83名怀疑有AIH-PBC的患者进行了回顾性分析,这些患者接受了组合治疗.
- 重新评估组织学并比较临床特征和长期结果.
- 基于诊断标准和疾病表现的肝移植 (LT) 无生存率的评估.
主要成果:
- 只有24%的人符合巴黎标准,而70%的人符合张的标准;然而,这两组都显示出类似的无LT生存率 (87.3%).
- 满足任何一个标准的患者在组织学上有更高的炎症和纤维化率.
- 与AIH-PBC患者 (87%) 相比,患有PBC和严重肝炎的患者的LT无生存率显着较低 (65%).
结论:
- 许多AIH-PBC患者成功接受组合治疗,但不符合确定的诊断标准.
- 巴黎和张的标准可能不能完全捕捉AIH-PBC的频谱.
- 建议更广泛地应用联合治疗,特别是在PBC和肝炎患者中,需要改善诊断共识.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
156
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
156
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84


